MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Recursion Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

5.47 2.82

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.2

Max

5.6

Schlüsselkennzahlen

By Trading Economics

Einkommen

31M

-172M

Verkäufe

4.4M

19M

Gewinnspanne

-899.843

Angestellte

800

EBITDA

44M

-148M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+16.67% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-405M

2.1B

Vorheriger Eröffnungskurs

2.65

Vorheriger Schlusskurs

5.47

Nachrichtenstimmung

By Acuity

50%

50%

149 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Okt. 2025, 23:30 UTC

Heiße Aktien

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2. Okt. 2025, 21:21 UTC

Ergebnisse

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3. Okt. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2. Okt. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2. Okt. 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2. Okt. 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2. Okt. 2025, 22:54 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Scales's JV Buyout Lauded by Bull -- Market Talk

2. Okt. 2025, 22:54 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Forex and Fixed Income Roundup: Market Talk

2. Okt. 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2. Okt. 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Okt. 2025, 21:17 UTC

Akquisitionen, Fusionen, Übernahmen

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2. Okt. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

2. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Okt. 2025, 20:49 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2. Okt. 2025, 20:00 UTC

Akquisitionen, Fusionen, Übernahmen

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2. Okt. 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2. Okt. 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2. Okt. 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2. Okt. 2025, 18:43 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer-Vergleich

Kursveränderung

Recursion Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

16.67% Vorteil

12-Monats-Prognose

Durchschnitt 5.95 USD  16.67%

Hoch 8 USD

Tief 3 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Recursion Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

1

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

4.15 / 4.75Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

149 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat